PMID- 33159239 OWN - NLM STAT- MEDLINE DCOM- 20210113 LR - 20211204 IS - 1432-0584 (Electronic) IS - 0939-5555 (Linking) VI - 100 IP - 1 DP - 2021 Jan TI - Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide. PG - 169-180 LID - 10.1007/s00277-020-04273-2 [doi] AB - The purpose of our study is to identify the efficacy of ruxolitinib in human leukocyte antigen (HLA) haploidentical hematopoietic stem cell transplantation (haplo-HSCT) recipients with multidrug-resistant (MDR)-graft-versus-host disease (GVHD, n = 34). MDR-GVHD was defined as GVHD showing no improvement after at least 3 types of treatments. The median number of previous GVHD-therapies was 4 for both MDR-acute GVHD (aGVHD) and MDR-chronic GVHD (cGVHD). For MDR-aGVHD (n = 15), the median time to response was 10 days (range 2 to 65), and the overall response rate (ORR) was 60.0% (9/15), including 40.0% (6/15) complete response (CR) and 20.0% (3/15) partial response (PR). The 1-year probability of overall survival after ruxolitinib was 66.7%. The rates of hematologic and infectious toxicities were 73.3% and 46.7% after ruxolitinib treatment. For MDR-cGVHD (n = 19), the median time to response was 29 days (range 6 to 175), and the ORR was 89.5% (17/19), including 26.3% (5/19) CR and 63.2% (12/19) PR. All patients remained alive until our last follow-up. The rates of hematologic and infectious toxicities were 36.8% and 47.4% after ruxolitinib treatment. Ruxolitinib is an effective salvage treatment for MDR-GVHD in haplo-HSCT recipients. FAU - Zhao, Jiao-Yu AU - Zhao JY AD - Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. AD - Department of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan, 030001, China. FAU - Liu, Si-Ning AU - Liu SN AD - Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. FAU - Xu, Lan-Ping AU - Xu LP AD - Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. AD - Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, 2019RU029, China. FAU - Zhang, Xiao-Hui AU - Zhang XH AD - Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. FAU - Wang, Yu AU - Wang Y AD - Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. FAU - Chen, Yu-Hong AU - Chen YH AD - Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. FAU - Liu, Kai-Yan AU - Liu KY AD - Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. FAU - Huang, Xiao-Jun AU - Huang XJ AD - Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. AD - Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, 2019RU029, China. AD - Peking-Tsinghua Center for Life Sciences, Beijing, 100044, China. FAU - Mo, Xiao-Dong AU - Mo XD AUID- ORCID: 0000-0002-9881-7945 AD - Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. mxd453@163.com. AD - Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, 2019RU029, China. mxd453@163.com. LA - eng PT - Journal Article DEP - 20201107 PL - Germany TA - Ann Hematol JT - Annals of hematology JID - 9107334 RN - 0 (Nitriles) RN - 0 (Pyrazoles) RN - 0 (Pyrimidines) RN - 82S8X8XX8H (ruxolitinib) RN - 8N3DW7272P (Cyclophosphamide) SB - IM MH - Adolescent MH - Adult MH - Child MH - Child, Preschool MH - *Cyclophosphamide MH - Drug Resistance, Multiple/*drug effects/physiology MH - Female MH - Follow-Up Studies MH - Graft vs Host Disease/diagnosis/*drug therapy MH - *Hematopoietic Stem Cell Transplantation/trends MH - Humans MH - Male MH - Middle Aged MH - Nitriles MH - Pyrazoles/*therapeutic use MH - Pyrimidines MH - Retrospective Studies MH - *Salvage Therapy/trends MH - *Transplantation, Haploidentical/trends MH - Transplantation, Homologous/trends MH - Treatment Outcome MH - Young Adult OTO - NOTNLM OT - Graft-versus-host disease OT - Haploidentical OT - Hematopoietic stem cell transplantation OT - Multidrug-resistant OT - Ruxolitinib EDAT- 2020/11/08 06:00 MHDA- 2021/01/14 06:00 CRDT- 2020/11/07 05:34 PHST- 2019/11/27 00:00 [received] PHST- 2020/05/04 00:00 [accepted] PHST- 2020/11/08 06:00 [pubmed] PHST- 2021/01/14 06:00 [medline] PHST- 2020/11/07 05:34 [entrez] AID - 10.1007/s00277-020-04273-2 [pii] AID - 10.1007/s00277-020-04273-2 [doi] PST - ppublish SO - Ann Hematol. 2021 Jan;100(1):169-180. doi: 10.1007/s00277-020-04273-2. Epub 2020 Nov 7.